Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ocugen, Inc.
  6. News
  7. Summary
    OCGN   US67577C1053

OCUGEN, INC.

(OCGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocugen, Inc. (OCGN)

07/23/2021 | 01:31pm EDT

BENSALEM, Pa., July 23, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming August 16, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Ocugen, Inc.  ("Ocugen" or the "Company") (NASDAQ: OCGN) securities between February 2, 2021 and June 10, 2021, inclusive (the "Class Period").

Investors suffering losses on their Ocugen investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

Ocugen is a biopharmaceutical company. Pursuant to an agreement with Bharat Biotech, Ocugen has the exclusive right to develop, manufacture, and commercialize COVAXIN, a vaccine candidate for COVID-19.

On June 10, 2021, Ocugen announced that it would submit a biologics license application ("BLA") for COVAXIN, which has a longer approval process than an Emergency Use Authorization ("EUA") application, and that it anticipated conducting an additional clinical trial to support the submission.

On this news, the Company's share price fell $2.62 per share, or 28%, to close at $6.69 per share on June 10, 2021, thereby injuring investors.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the information submitted to the FDA was insufficient to support an EUA, (2) Ocugen would not file an Emergency Use Authorization with the FDA; and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Ocugen securities during the Class Period, you may move the Court no later than August 16, 2021 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Cision
View original content:https://www.prnewswire.com/news-releases/deadline-reminder-law-offices-of-howard-g-smith-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-ocugen-inc-ocgn-301340023.html

SOURCE Law Offices of Howard G. Smith


© PRNewswire 2021
All news about OCUGEN, INC.
09/17OCUGEN INC : . Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/17INSIDER SELL : Ocugen
MT
09/16SOCIAL BUZZ : Wallstreetbets Stocks Largely in Negative Territory on Pre-Bell Th..
MT
09/15OCUGEN, INC. : Regulation FD Disclosure (form 8-K)
AQ
09/14OCUGEN : Thinking about buying stock in FuelCell Energy, Farmmi, Aterian, Vinco ..
PR
09/10OCUGEN INVESTIGATION INITIATED BY FO : Kahn Swick & Foti, LLC Investigates the O..
BU
09/08OCUGEN, INC. : Other Events (form 8-K)
AQ
09/07OCUGEN : to Present at Upcoming Citi and H.C. Wainwright Investment Conferences
AQ
09/01EXPERT SERIES : The truth about COVID-19 variants
PU
08/20OCUGEN INC : . Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
More news
Analyst Recommendations on OCUGEN, INC.
More recommendations